BCMA-CD3 mutant Fc - 200uL

BCMA (B cell maturation antigen) is a type III membrane protein encoded by the TNFRSF17 gene and expressed on mature B cells and plasma cells. BCMA binding to TNFSF13B/BAFF results in activation of the NF-κB and MAPK8/ JNK signaling pathways. BCMA is highly expressed in malignant plasma cells and currently serves as an excellent therapeutic target for multiple myeloma. CD3 is a protein complex expressed by all T cells that facilitates antigen recognition. ProMab’s PM-LNP-0110 nanoparticles contain an mRNA encoding an anti-BCMA, anti-CD3 bispecific antibody with a modified human IgG Fc domain (L234A, L235A and P329G). The nanoparticles are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery in vitro and in vivo.